Johnson & Johnson will open the "buy, buy, buy" mode in the fields of eye care, orthopedics and cardiovascular!

Johnson & Johnson CEO Joaquin Duato said the company will look for opportunities to merge or acquire companies to add value
to its focus areas such as eye care, surgical robotics, orthopedics and cardiovascular products.
The industry said there were early signs
that Johnson & Johnson would be looking for acquisition opportunities in key areas such as eye care, orthopedics and cardiovascular products.
In recent years, Johnson & Johnson is reforming its business, divesting its consumer health business to focus on pharmaceuticals and medical devices
.
In terms of divestitures, Johnson & Johnson sold its blood glucose monitoring company, LifeScan, to Platinum equity
in June 2018 for $2.
1 billion.
In 2017, Johnson & Johnson also announced the discontinuation of operations and withdrawal from the Animas insulin pump business, which was taken over by Medtronic
.
As Johnson & Johnson's traditional business, the diabetes business is clearly being abandoned
.
In terms of acquisitions, Johnson & Johnson has moved very frequently
in recent years.
For example, on November 1, 2022, Johnson & Johnson said it would acquire heart pump maker Abiomed with a cash advance of $380 per share
.
The transaction, valued at approximately $16.
6 billion, including debt and cash, is expected to close by the end of the
first quarter of 2023.
Upon completion of the transaction, Abiomet will operate
as an independent business of Johnson & Johnson's MedTech business.
It is worth mentioning that this acquisition is the first large-scale acquisition
since Johnson & Johnson announced the divestment of its consumer health business.
Analysts believe that the large-scale acquisition of Abiomed will expand Johnson & Johnson's layout in the cardiovascular track and improve its comprehensive strength
in the field of health care, especially in heart failure and rehabilitation.
In 2019, Johnson & Johnson announced that it would acquire surgical robotics company Auris Health
for $3.
4 billion in cash consideration and an additional milestone payment of up to $2.
35 billion.
The acquisition amount is equivalent to approximately RMB 39 billion
.
It is reported that Auris is a private company, founded by surgical robot pioneer Frederic Moll, who is also one of the co-founders of the global surgical robot leader Intuitive Surgical, whose da Vinci surgical robot currently occupies a large share of the market
.
Johnson & Johnson said the deal would complement
the acquisition of Orthotaxy.
In February 2018, Johnson & Johnson acquired Orthotaxy, a French developer of surgical software technology, to build a next-generation robotic-assisted orthopedic surgery solution
that is cheaper, more efficient, and easier to use.
In September 2018, Johnson & Johnson also acquired Emerging Implant Technologies, a German manufacturer of 3D printed spinal implants, for an undisclosed
amount.
EIT is a privately held manufacturer of 3D printed titanium intervertebral implants for spinal fusion surgery
.
.
.
.
.
.
.
In fact, in recent years, not only Johnson & Johnson, but also many pharmaceutical companies around the world are frequently launching acquisitions
.
The industry expects that in the future, multinational pharmaceutical giants will continue to become the "main force"
of huge acquisitions in the industry.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.